Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | VP, Biology | December 11, 2018 | December 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date December 11, 2018 · Filed December 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 6,550 |
Ending reported balance
After 2018-12-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-12-11 · Exercise / conversion · Acquired 4,115 · Balance 8,194 F1: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Row 2 · 2018-12-11 · Tax withholding · Disposed 1,644 · Balance 6,550 F4: The Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in September 2018. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the lock-up agreement. F2: Represents the closing price of the Company's common shares in U.S. dollars on December 10, 2018, converted to a Canadian dollar amount for purposes of net settlementment calculations. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2018-12-31 | Direct | 0 |
Reported balance
After 2018-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-11 · Exercise / conversion · Disposed 4,115 · Balance 0 F1: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3: The shares subject to the option fully vested on December 31, 2012. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
F2: Represents the closing price of the Company's common shares in U.S. dollars on December 10, 2018, converted to a Canadian dollar amount for purposes of net settlementment calculations.
F3: The shares subject to the option fully vested on December 31, 2012.
F4: The Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in September 2018. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the lock-up agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2018 Filed Dec 13, 2018 18:56 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,115 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001171843-18-008430 · ownership.xml · derivative · entry 3 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,115 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 18:56 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,644 | $7.00 | $11,508.00 |
DisclosureSEC source: 0001171843-18-008430 · ownership.xml · nonDerivative · entry 2 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,550 F4 · shares: The Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in September 2018. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the lock-up agreement. F2 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 10, 2018, converted to a Canadian dollar amount for purposes of net settlementment calculations. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 18:56 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 4,115 | $3.07 | $12,633.05 |
DisclosureSEC source: 0001171843-18-008430 · ownership.xml · nonDerivative · entry 1 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:45 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001171843-18-001918 · formfour.xml · derivative · entry 1 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2028-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:55 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,748 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001171843-18-001149 · f4_cohen021318.xml · derivative · entry 3 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 26,748 shares Expires 2018-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on January 31, 2012. The date the option became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:55 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 22,669 | $3.50 | $79,341.50 |
DisclosureSEC source: 0001171843-18-001149 · f4_cohen021318.xml · nonDerivative · entry 2 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,079 F2 · price: Represents the closing price of the Company's common shares on February 09, 2018, which was converted to $4.41 Canadian for purposes of net settlement calculations. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:55 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 26,748 | $3.71 | $99,235.08 |
DisclosureSEC source: 0001171843-18-001149 · f4_cohen021318.xml · nonDerivative · entry 1 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 22:43 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001171843-17-006253 · formfour.xml · derivative · entry 1 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 20:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001171843-17-001510 · f4_cohen031417.xml · derivative · entry 1 COHEN CHARLES J. · CIK 0001619967 · VP, Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2027-03-12 F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.